[go: up one dir, main page]

WO2024191139A1 - Composition pour la prévention ou le traitement du cancer à kras mutant - Google Patents

Composition pour la prévention ou le traitement du cancer à kras mutant Download PDF

Info

Publication number
WO2024191139A1
WO2024191139A1 PCT/KR2024/003046 KR2024003046W WO2024191139A1 WO 2024191139 A1 WO2024191139 A1 WO 2024191139A1 KR 2024003046 W KR2024003046 W KR 2024003046W WO 2024191139 A1 WO2024191139 A1 WO 2024191139A1
Authority
WO
WIPO (PCT)
Prior art keywords
kras
cancer
amino acid
mutation
mutant cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/KR2024/003046
Other languages
English (en)
Korean (ko)
Inventor
김경진
김욱일
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ST Pharm Co Ltd
Original Assignee
ST Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ST Pharm Co Ltd filed Critical ST Pharm Co Ltd
Publication of WO2024191139A1 publication Critical patent/WO2024191139A1/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to a composition for preventing or treating KRAS mutant cancer, and more particularly, to a pharmaceutical composition for preventing or treating KRAS G12 mutant cancer comprising a triazolopyrimidinone derivative and a MEK inhibitor.
  • the KRAS protein encoded by the KRAS gene belongs to the RAS protein family and is a small GTP-ase involved in intracellular signal transduction.
  • the KRAS protein exists in the cell in an inactive state (KRAS-GDP) or an activated state (KRAS-GTP), and is involved in cell signaling pathways such as MAPK and PI3K that regulate cell survival, proliferation, and apoptosis.
  • KRAS mutations are caused by genetic alterations in the gene encoding KRAS, and they keep Ras signaling activated, causing cell proliferation and tumorigenesis. These mutations are known to increase resistance to apoptosis in pancreatic cancer cells, thereby causing anticancer drug resistance. KRAS mutations can be classified into various types depending on changes in location and sequence. Representative mutations include G12D, G12V, G12R, G12C, in which glycine, the amino acid residue at position 12, is substituted with aspartic acid, valine, arginine, or cysteine, and G13D, G13V, G13H, in which glycine, the amino acid residue at position 13, is substituted with aspartic acid, valine, or histidine. It has been reported that the oncological aspects differ depending on the type of KRAS mutation, the effectiveness of anticancer treatment can be determined, and consequently, there is a difference in the patient's survival rate.
  • KRAS mutations disrupt the ability of KRAS to hydrolyze GTP, resulting in functional changes in the KRAS protein and the subsequent transduction of growth signals to the nucleus, which promotes cell growth and division and contributes to oncogenesis.
  • G12D, G12V, and G13D mutations in KRAS disrupt GAP activity, allowing KRAS to remain bound to GTP, locking KRAS in an activated state by tyrosine kinases, and persistently activating downstream signaling pathways (e.g., PI3K, RAF-MEK-ERK (MAPK), RAL-GEF, etc.).
  • Targeted therapies that block Ras-GTPase are being developed as treatments targeting KRAS, but the lack of a binding pocket in GTP-bound-KRAS makes it difficult to develop appropriate treatments because it directly interferes with the binding of small molecules that target KRAS.
  • conventional KRAS G12C gene mutation treatments clinical trials are being conducted in combination with inhibitors of PD-1, EGFR, and SHP2, such as Sotorasib and Adagrasib, for non-small cell lung cancer, colorectal cancer, and other solid cancers.
  • MEK Mitogen-activated protein kinase
  • RAS/RAF/MEK/ERK signaling pathway which regulates cell growth and affects tumorigenesis.
  • MEK inhibitors which selectively inhibit MEK protein, have shown significant anticancer effects in KRAS-mutant cancers through activation of the RAS/RAF/MEK pathway.
  • inherently acquired resistance to MEK inhibitors has been frequently observed in clinical trials, and there is a need for the development of improved therapeutic regimens to overcome resistance to MEK inhibitors and exhibit effective anticancer activity.
  • a triazolopyrimidinone derivative compound having tankyrase inhibitory activity when administered in combination with a MEK inhibitor, has a potent anticancer effect on KRAS mutant cancer, thereby completing the present invention as a significant therapeutic agent capable of overcoming resistance to MEK inhibitors.
  • One object of the present invention is to provide a pharmaceutical composition for preventing or treating KRAS G12 mutant cancer, comprising a triazolopyrimidinone derivative compound or a pharmaceutically acceptable salt thereof; and a MEK inhibitor as active ingredients.
  • Another object of the present invention is to provide a method for preventing or treating KRAS G12 mutant cancer, comprising the step of administering a triazolopyrimidinone derivative compound or a pharmaceutically acceptable salt thereof; and a MEK inhibitor to a subject who has developed or is at risk of developing KRAS G12 mutant cancer.
  • Another object of the present invention is to provide a triazolopyrimidinone derivative compound or a pharmaceutically acceptable salt thereof; and a MEK inhibitor for the prevention or treatment of KRAS G12 mutant cancer.
  • One aspect of the present invention for achieving the above object provides a pharmaceutical composition for preventing or treating KRAS G12 mutant cancer, comprising a triazolopyrimidinone derivative compound of the following chemical formula 1 or a pharmaceutically acceptable salt thereof; and a MEK inhibitor as active ingredients:
  • the present inventors confirmed an excellent anticancer effect on KRAS G12 mutant cancer when a triazolopyrimidinone derivative compound of the above chemical formula 1 and a MEK inhibitor were administered together, and completed the present invention.
  • KRAS belongs to the RAS protein family and is a small GTP-ase involved in intracellular signal transduction.
  • the KRAS gene is one of the Ras genes, which are oncogenes involved in tumorigenesis, and is a factor constituting part of the RAS/MAPK, a cell signal transduction pathway that regulates cell growth, cell maturation, and cell death.
  • the KRAS protein may be a wild-type human KRAS protein represented by the amino acid sequence presented in Genbank Accession No. AGC09594, and may be composed of, for example, the amino acid sequence of SEQ ID NO: 1, but is not limited thereto.
  • KRAS mutation or “KARS mutation” may be a genetic modification of the KRAS gene in which some amino acids of the KRAS protein encoded therefrom are substituted, deleted or inserted.
  • the KARS mutation may be a substitution of the 12th amino acid (G12), the 13th amino acid (G13) or the 146th amino acid (A146) of the KRAS protein with another amino acid, and may be, for example, a KRAS G12C mutation, a KRAS G12D mutation, a KRAS G12V mutation, a KRAS G12R mutation, a KRAS G12S mutation, a KRAS G12A mutation, a KRAS G13C mutation, a KRAS G13D mutation, a KRAS G13V mutation, a KRAS G13H mutation, a KRAS A146T mutation and a KRAS A146V mutation, but is not limited thereto.
  • “genetic modification” means a change in the form or properties of a gene due to a structural change in DNA that may occur during the replication and division of the gene.
  • a genetic modification may occur in a gene base sequence, and may occur in the form of a base transposition, a base inversion, a missense mutation, a termination mutation, a base duplication, a base deletion, a reversion mutation, and a suppressor mutation.
  • the KRAS gene mutation may appear in the form of a missense mutation, which means a genetic mutation phenomenon involved in protein synthesis, in which one of the three base sequences forming an amino acid is changed to code for a different amino acid.
  • amino acid means an organic compound that constitutes a monomer unit of peptides including proteins. It is composed of carbon, hydrogen, oxygen, nitrogen, etc., and includes functional groups such as an amino group and a carboxyl group. There are more than 500 naturally occurring amino acids, and 20 of them have their own designated codons. In addition to their role as protein residues, amino acids are involved in various processes such as neurotransmitters and biosynthesis.
  • the amino acids may be, but are not limited to, alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine.
  • KRAS G12 mutation may be a substitution of glycine (G), an amino acid residue at the 12th position of the KRAS protein, with valine (V), aspartic acid (D), serine (S), alanine (A), arginine (R), or cysteine (C), and may specifically be, but is not limited to, G12V, G12D, G12S, G12A, G12R, or G12C.
  • KRAS G12V mutation in which the amino acid residue glycine at position 12 in the amino acid sequence of sequence number 1 is substituted with valine;
  • KRAS G12R mutation in which the amino acid residue glycine at position 12 in the amino acid sequence of sequence number 1 is substituted with arginine
  • It may be at least one selected from the group consisting of KRAS G12C mutations in which the amino acid residue glycine at position 12 in the amino acid sequence of sequence number 1 is substituted with cysteine.
  • cancer is a disease related to the regulation of cell death, and is a disease caused by excessive cell proliferation when the normal balance of cell death is disrupted, and has the same meaning as commonly used in the art.
  • the cancer includes both malignant tumors and benign tumors.
  • the cancer may be a solid cancer, and specifically may be one or more solid cancers selected from the group consisting of colon cancer, lung cancer, colon cancer, gastric cancer, hepatocellular cancer, breast cancer, medulloblastoma, melanoma, pancreatic adenocarcinoma, thyroid cancer, and prostate cancer, but is not limited thereto.
  • the cancer may be a KRAS mutant cancer.
  • KRAS mutant cancer refers to a cancer having a genetic mutation in the KRAS gene encoding a GTP hydrolase belonging to the RAS super protein family, and KRAS mutation is known to be involved in the carcinogenesis process by promoting cell growth and division.
  • the KRAS mutant cancer may be a KRAS G12 mutant cancer in which a KRAS G12 mutation appears.
  • the composition for preventing or treating KRAS G12 mutant cancer of the present invention may have a therapeutic effect on all cancers exhibiting a KRAS G12 mutation.
  • the above KRAS G12 mutant cancer may be a MEK inhibitor-resistant cancer, and may refer to a cancer that has developed intrinsic resistance and/or acquired resistance to MEK inhibitors due to KRAS G12 mutations, etc.
  • Intrinsic resistance means that the cancer does not respond to drug treatment with a decrease in the size of the cancer
  • acquired resistance means that a cancer in a progressive disease state shows new metastatic lesions or a cancer that has previously been in remission grows again.
  • the composition of the present invention exhibits an excellent synergistic effect on the inhibition of cell death and tumor formation of KRAS mutant, particularly KRAS G12 mutant cancer cell lines.
  • the triazolopyrimidinone derivative compound may be a compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof.
  • the compound represented by the above chemical formula 1 may be referred to as 5-(4-(2,6-difluoro-4-(2-methoxyethoxy)phenyl)piperazin-1-yl)-3-methyl-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one.
  • the triazolopyrimidinone derivative compound of the above chemical formula 1 may inhibit the activity of Tankyrase enzyme, and specifically, may inhibit the activity of Tankyrase 1 (TNKS1), Tankyrase 2 (TNKS2), or both.
  • the triazolopyrimidinone derivative compound represented by the above chemical formula 1 or a pharmaceutically acceptable salt thereof can exhibit an effect of suppressing tumor formation by inhibiting tankyrase enzyme activity and regulating the WNT/ ⁇ -catenin signaling pathway of cancer cells, thereby being useful for the prevention or treatment of KRAS G12 mutant cancer.
  • the triazolopyrimidinone derivative compound of the above chemical formula 1 may exist in the form of a pharmaceutically acceptable salt.
  • pharmaceutically acceptable salt means any organic or inorganic addition salt of the above compound at a concentration that is relatively non-toxic and harmless to a patient and has an effective effect, and the side effects due to the salt do not reduce the beneficial efficacy of the compound represented by the chemical formula 1.
  • Acid addition salts are prepared by conventional methods, for example, by dissolving the compound in an excess of an aqueous acid solution and precipitating the salt using a water-miscible organic solvent, for example, methanol, ethanol, acetone or acetonitrile.
  • a water-miscible organic solvent for example, methanol, ethanol, acetone or acetonitrile.
  • Equimolar amounts of the compound and an acid or alcohol (e.g., glycol monomethyl ether) in water can be heated, and the mixture can then be evaporated to dryness, or the precipitated salt can be filtered off with suction.
  • organic acids and inorganic acids can be used as free acids, and inorganic acids such as hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, and tartaric acid can be used, and organic acids such as methanesulfonic acid, p-toluenesulfonic acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanillic acid, and hydroiodic acid can be used, but are not limited thereto.
  • inorganic acids such as hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, and tartaric acid
  • organic acids such as methanesul
  • Pharmaceutically acceptable salts of the compounds of the present invention include salts of acidic or basic groups which may be present in the compounds of Formula 1, unless otherwise indicated.
  • pharmaceutically acceptable salts may include sodium, calcium and potassium salts of hydroxy groups
  • other pharmaceutically acceptable salts of amino groups include hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, dihydrogen phosphate, acetate, succinate, citrate, tartrate, lactate, mandelate, methanesulfonate (mesylate) and p-toluenesulfonate (tosylate) salts, and the like, and can be prepared by methods for preparing salts known in the art.
  • any salt of the triazolopyrimidinone derivative of the above chemical formula 1 that is a pharmaceutically acceptable salt and exhibits inhibitory activity against tankyrase 1 and/or tankyrase 2 equivalent to that of the triazolopyrimidinone derivative compound of the above chemical formula 1 may be used without limitation.
  • the MEK inhibitor is a substance that inhibits the function of MEK (Mitogen-activated protein kinase), and may be a compound having an activity of inhibiting MEK1 and/or MEK2, or a pharmaceutically acceptable salt thereof.
  • the above MEK inhibitors are known to have single anticancer activity in a number of human cancer models, and provide an effect of inhibiting tumor cell proliferation through inhibition of MEK1 and MEK2.
  • the MEK inhibitors include Trametinib, Selumetinib, Mirdametinib, Binimetinib, Cobimetinib, Pimasertib, Pelitinib, Refametinib, Zaphnometinib, Honokiol, U0126-EtOH, PD184352, PD58059, BIX-02189, BIX-02188, TAK-733, AZD8330, SL-327, GDC-0623, BI-847325, RO5126766, PD318088, PD184161, GW284543 and Any one or more selected from the group consisting of APS-2-79, but is not limited thereto.
  • treatment refers to an intervention to alter the natural course of an individual or cell having a disease, which may be performed during the progression of the pathological condition or to prevent it.
  • the desired therapeutic effect includes preventing the occurrence or recurrence of the disease, alleviating symptoms, reducing any direct or indirect pathological consequences of the disease, preventing metastasis, reducing the rate of disease progression, alleviating or temporarily alleviating the disease condition, and reversing or improving the prognosis.
  • the present invention includes all acts that improve the course of cancer by administering the pharmaceutical composition of the present invention.
  • prevention means any act of inhibiting or delaying the occurrence, spread, and recurrence of KRAS G12 mutant cancer by administering the composition of the present invention.
  • composition of the present invention may additionally contain a pharmaceutically acceptable carrier, diluent or excipient, and may be formulated and used in various forms, such as oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups and aerosols, and injections of sterile injection solutions, according to conventional methods according to each intended use, and may be administered orally or through various routes, including intravenous, intraperitoneal, subcutaneous, rectal and topical administration.
  • a pharmaceutically acceptable carrier such as powders, granules, tablets, capsules, suspensions, emulsions, syrups and aerosols
  • injections of sterile injection solutions according to conventional methods according to each intended use, and may be administered orally or through various routes, including intravenous, intraperitoneal, subcutaneous, rectal and topical administration.
  • compositions of the present invention may further comprise fillers, anticoagulants, lubricants, wetting agents, fragrances, emulsifiers, preservatives and the like.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations are formulated by mixing at least one excipient, such as starch, calcium carbonate, sucrose, lactose, gelatin, etc., with the composition.
  • excipients such as starch, calcium carbonate, sucrose, lactose, gelatin, etc.
  • lubricants such as magnesium stearate and talc may be used.
  • Oral liquid preparations include suspensions, solutions, emulsions, syrups, etc., and in addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, flavoring agents, and preservatives may be included.
  • Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories.
  • Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.
  • Suppository bases may include withepsol, macrogol, Tween 61, cacao butter, laurin butter, glycerogelatin, and the like.
  • injections may include conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifiers, stabilizers, and preservatives.
  • the pharmaceutical composition can be administered to a subject in a pharmaceutically effective amount.
  • administration refers to introducing the pharmaceutical composition of the present invention into a subject in any appropriate manner, and the administration route can be administered through various routes, such as oral or parenteral, as long as it can reach the target tissue.
  • routes include, but are not limited to, oral, intramuscular, intravenous, intraarterial, subcutaneous, intraperitoneal, pulmonary, and nasal. It is important to administer an amount that can obtain the maximum effect with the minimum amount without side effects by considering all of the above factors, and this can be easily determined by those skilled in the art.
  • the triazolopyrimidinone derivative compound and the MEK inhibitor may be administered simultaneously or at different times.
  • Another aspect of the present invention for achieving the above object provides a method for preventing or treating KRAS G12 mutant cancer, comprising the step of administering a triazolopyrimidinone derivative compound of the above chemical formula 1 or a pharmaceutically acceptable salt thereof; and a MEK inhibitor to a subject who has developed or is at risk of developing KRAS G12 mutant cancer.
  • compositions of the present invention are administered to a subject suspected of having or at risk for developing a disease, disorder, or condition described herein.
  • compositions of the present invention are administered to a subject, such as a patient already suffering from a disorder described herein, in an amount sufficient to treat or at least partially arrest the symptoms of a disease, disorder, or condition described herein. Amounts effective for such use will depend on the severity and course of the disease, disorder, or condition, previous treatment, the subject's health status and responsiveness to the drugs, and the judgment of the physician or veterinarian.
  • the triazolopyrimidinone derivative compound of the chemical formula 1 and the MEK inhibitor can be administered to a subject in a pharmaceutically effective amount.
  • subject in the present invention means any animal, including mammals such as humans, that has developed or can develop a cancer disease including solid cancer, specifically KRAS G12 mutant cancer, and typically may be a human or an animal other than a human that can exhibit a beneficial effect by treatment using the composition of the present invention, but includes without limitation any subject that has symptoms of a cancer disease or is likely to have such symptoms.
  • KRAS G12 mutant cancer can be effectively prevented, improved, or treated.
  • the term “administration” means introducing a given substance into an animal, including a human, by any appropriate method, and the route of administration of the composition of the present invention may be oral or parenteral administration through any general route as long as it can reach the target tissue.
  • the composition of the present invention may be administered by any device through which the active ingredient can move to the target cell.
  • pharmaceutically effective amount in the present invention means an amount sufficient to prevent and/or treat a disease at a reasonable benefit/risk ratio applicable to medical use.
  • An appropriate dosage and frequency of administration can be selected according to a method known in the art, and the dosage and frequency of administration of the pharmaceutical composition of the present invention actually administered can be appropriately determined by various factors such as the type of symptom to be treated, administration route, sex, health condition, diet, age and weight of the subject, and the severity of the disease, and this can be easily determined by a person skilled in the art.
  • the pharmaceutical composition of the present invention may further comprise a known anticancer agent in addition to a triazolopyrimidinone derivative compound or a pharmaceutically acceptable salt thereof and a MEK inhibitor, and may be used in combination with other treatments known to treat KRAS G12 mutant cancer.
  • Other treatments include, but are not limited to, chemotherapy, radiation therapy, hormone therapy, bone marrow transplantation, stem-cell replacement therapy, other biological therapy, immunotherapy, and the like.
  • Another aspect of the present invention for achieving the above object provides a use of a triazolopyrimidinone derivative compound of the above chemical formula 1 or a pharmaceutically acceptable salt thereof; and a MEK inhibitor for preventing or treating KRAS G12 mutant cancer.
  • the present invention provides a use of a triazolopyrimidinone derivative compound of the above formula 1 or a pharmaceutically acceptable salt thereof; and a MEK inhibitor for preparing a medicament for preventing or treating KRAS G12 mutant cancer.
  • Combination therapy of a triazolopyrimidinone derivative compound according to the present invention and a MEK inhibitor can exhibit a remarkable synergistic effect on anticancer activity and tumorigenesis inhibition against KRAS G12 mutant cancer.
  • Figure 1 is a graph showing the change in tumor volume over 4 weeks after single or combined administration of a triazolopyrimidinone derivative and a MEK inhibitor (trametinib) in a KRAS G12 mutant xenograft animal model.
  • Trametinib was purchased from TargetMol Chemicals, and cobimetinib, selumetinib, mirdametinib, and binimetinib were purchased and used from Selleck Chemicals.
  • SW480 (CCL-228), SW620 (CCL-227), COLO320DM (CCL-220), A549 (CCL-185), H358 (CRL-5807), DLD-1 (CCL-221), HCT-15 (CCL-225), LS-1034 (CRL-2158), KM12C (CVCL-9547), and COLO205 (CCL-222) cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA), and cell line identification was authenticated using Short Tandem Repeat (STR) analysis according to the ANSI/ATCC ASN-0002-2012 guidelines.
  • STR Short Tandem Repeat
  • the degree of cancer cell death according to drug treatment was measured through absorbance, and the CI value was derived from the FA value (Fraction-Affected value) of each combination according to the Chou-Talalay method using CompuSyn software (ComboSyn, Inc., Paramus, NJ, USA).
  • the combination index (CI) for cancer cell death following co-administration with various MEK inhibitors in cancer cell lines expressing KRAS mutations was measured.
  • the colon cancer cell line SW480 expressing KRAS G12V mutation was seeded in 96-well plates at a density of 3,000 cells per well in triplicate per group.
  • MEK inhibitors trametinib, selumetinib, mirdametinib, binimetinib, or cobimetinib (0-50 nM; 0, 3.125, 6.25, 12.5, 25, and 50 nM), individually or in combination with compound A (0-20 uM; 0, 1.25, 2.5, 5, 10, and 20 uM), were added to the wells.
  • the combination index in all experimental groups was less than 0.7, confirming that combined treatment with compound A and a MEK inhibitor exhibited a synergistic anticancer effect on KRAS G12 mutant cancer.
  • KRAS mutations exist in various types depending on changes in location and sequence, and the oncological aspects and anticancer effects may vary depending on the type of KRAS mutation. Therefore, the anticancer effects of the combination therapy of the present invention were compared according to the type of KRAS mutation.
  • SW480 and SW620 (G12V), COLO320DM (G12D), A549 (G12S), H358 (G12C) were used as KRAS G12 mutant cancer cell lines; DLD-1 and HCT-15 (G13D) were used as KRAS G13 mutant cancer cell lines; LS-1034 (A146T) was used as KRAS A146 mutant cancer cell line, and KM12C, COLO205, and H358 were used as wild-type cell lines without mutations.
  • the combination therapy according to the present invention exhibits excellent anticancer activity specifically against KRAS G12 mutant cancers among cancers in which KRAS mutations appear, and therefore, the combination therapy according to the present invention can be expected to exhibit excellent anticancer effects in patients with KRAS G12 mutations.
  • tumor volumes were measured in xenograft animal models.
  • BALB/c Nude mice (strain: Mus Musculus, age: 6-8 weeks, sex: female, body weight: 18-22 g, supplier: Zhejiang Vital River Laboratory Animal Technology Co., Ltd.) were subcutaneously implanted with SW480 tumor cells (5 ⁇ 10 6 ) into the flank of each mouse. On day 6 after tumor implantation, when the average tumor volume reached 124 mm 3 , the animals were grouped for drug administration. Compound A and/or trametinib were orally administered once daily for 28 days at 10, 30 mg/kg and/or 0.2 mg/kg, respectively. Before the start of drug administration, the tumor sizes of the mice were measured in two dimensions using a caliper, and measured twice a week after drug administration, and the results of the changes in tumor volumes were compared among the groups, and the results are shown in Fig. 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique pour la prévention ou le traitement du cancer à mutation KRAS G12, comprenant un dérivé de triazolopyrimidinone et un inhibiteur de MEK. La composition selon la présente invention présente un effet synergique significatif sur l'activité anticancéreuse contre le cancer à mutation KRAS G12 et l'inhibition de la formation tumorale, et peut ainsi être utile en tant que complexe ou régime thérapeutique contre le cancer à mutation KRAS G12.
PCT/KR2024/003046 2023-03-10 2024-03-08 Composition pour la prévention ou le traitement du cancer à kras mutant Pending WO2024191139A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20230032109 2023-03-10
KR10-2023-0032109 2023-03-10

Publications (1)

Publication Number Publication Date
WO2024191139A1 true WO2024191139A1 (fr) 2024-09-19

Family

ID=92756095

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2024/003046 Pending WO2024191139A1 (fr) 2023-03-10 2024-03-08 Composition pour la prévention ou le traitement du cancer à kras mutant

Country Status (1)

Country Link
WO (1) WO2024191139A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013182546A1 (fr) * 2012-06-07 2013-12-12 F. Hoffmann-La Roche Ag Inhibiteurs de tankyrase à base de pyrazolopyrimidone et de pyrazolopyridone
KR101739003B1 (ko) * 2014-07-11 2017-05-23 에스티팜 주식회사 신규한 트리아졸로피리미디논 또는 트리아졸로피리디논 유도체, 및 이들의 용도
KR20210094570A (ko) * 2018-11-19 2021-07-29 암젠 인크 Krasg12c 억제제 및 하나 이상의 추가 제약 활성제를 포함하는 암 치료용 병용 요법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013182546A1 (fr) * 2012-06-07 2013-12-12 F. Hoffmann-La Roche Ag Inhibiteurs de tankyrase à base de pyrazolopyrimidone et de pyrazolopyridone
KR101739003B1 (ko) * 2014-07-11 2017-05-23 에스티팜 주식회사 신규한 트리아졸로피리미디논 또는 트리아졸로피리디논 유도체, 및 이들의 용도
KR20210094570A (ko) * 2018-11-19 2021-07-29 암젠 인크 Krasg12c 억제제 및 하나 이상의 추가 제약 활성제를 포함하는 암 치료용 병용 요법

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SCHOUMACHER MARIE, HUROV KRISTEN E., LEHÁR JOSEPH, YAN-NEALE YAN, MISHINA YUJI, SONKIN DMITRIY, KORN JOSHUA M., FLEMMING DAISY, JO: "Inhibiting Tankyrases Sensitizes KRAS-Mutant Cancer Cells to MEK Inhibitors via FGFR2 Feedback Signaling", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, SAN DIEGO, CA . PHILADELPHIA (PA, vol. 74, no. 12, 15 June 2014 (2014-06-15), San Diego, CA . Philadelphia (PA, pages 3294 - 3305, XP093209701, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-14-0138-T *
SHARON MCGONIGLE, ZHIHONG CHEN, JIAYI WU, PAUL CHANG, DONNA KOLBER-SIMONDS, KAREN ACKERMANN, NATALIE C. TWINE, JUE-LON SHIE, JINGZ: "E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling", ONCOTARGET, vol. 6, no. 38, 1 December 2015 (2015-12-01), XP055643133, DOI: 10.18632/oncotarget.5846 *
YOUNG-JU KWON; DONG YOUNG KIM; UK-IL KIM; XUE MENG; HO KYUN LEE; HYUNG TAE BANG; JAE-SUNG KIM; KYUNGJIN KIM: "Abstract 491: Tankyrase-selective inhibitor STP1002 reverses resistance to MEK inhibitors in colorectal cancer with KRAS mutations", CANCER RESEASRCH, UNIVERSITY OF CHICAGO PRESS, vol. 83, no. 7_Supplement, 1 April 2023 (2023-04-01), pages 491 - 491, XP009557346, ISSN: 0099-7374, DOI: 10.1158/1538-7445.AM2023-491 *

Similar Documents

Publication Publication Date Title
CA2802644C (fr) Agent anticancereux utilisant des composes ayant un effet inhibiteur de kinase en combinaison
EP2700403B1 (fr) Agent thérapeutique pour les tumeurs
US20120077837A1 (en) Anti-tumor agent
WO2021089005A1 (fr) Utilisation d'un inhibiteur de fgfr
WO2020211860A1 (fr) Composé de quinoléine ou sel pharmaceutiquement acceptable de celui-ci pour le traitement du sarcome d'ewing
EP4205746A1 (fr) Composé destiné à inhiber un mutant d'egfr et son utilisation
WO2022245089A1 (fr) Composition pour le traitement de la covid-19 comprenant de l'acide taurodésoxycholique ou un sel pharmaceutiquement acceptable correspondant en tant que principe actif
US20210369709A1 (en) EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
CN101222850A (zh) 治疗对药物有抗性的癌症的方法
WO2024191139A1 (fr) Composition pour la prévention ou le traitement du cancer à kras mutant
CN110840892A (zh) 酪氨酸激酶抑制剂与cdk4/6抑制剂联合在制备预防或治疗肿瘤疾病的药物中的用途
JP2024514098A (ja) ＥｒｂＢ２突然変異体を標的とする阻害薬の調製における化合物の使用
WO2016025621A1 (fr) Méthodes de traitement à l'aide d'un inhibiteur d'erk
CN112043698A (zh) 一组小分子药物在制备抑制肉瘤药物中的应用
WO2018068769A1 (fr) Utilisation de composés de type dihydroberbérine dans la préparation d'un produit destiné au traitement de maladies tumorales associées à la voie de signalisation stat3
WO2024191138A1 (fr) Polythérapie de dérivé de triazolopyrimidinone et d'inhibiteur de mek
AU2020276392B2 (en) Combination therapy for proliferative conditions
JP5794873B2 (ja) 抗腫瘍剤
CN114931644A (zh) 氧化磷酸化抑制剂在治疗β-连环蛋白活化突变肿瘤中的用途
WO2006102363A1 (fr) Procedes permettant de traiter ou prevenir la leucemie myelogene aigue
WO2021167175A1 (fr) Composition pharmaceutique utilisée dans la prévention ou le traitement du cancer comprenant un inhibiteur de signalisation mtor comme principe actif
CN105251023A (zh) AXL/c-Met抑制剂在制备逆转肾癌舒尼替尼耐药的药物中的应用
CN118161509B (zh) 一种mapk12抑制剂及其衍生物在制备抗肿瘤药物中的应用
CN115212211B (zh) 双去甲基汉防己甲素双甲酸乙酯与parp-1抑制剂联合治疗肿瘤的用途
WO2024191132A1 (fr) Composition pour la prévention ou le traitement du cancer contenant un inhibiteur de met et un inhibiteur de k-ras

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24771139

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE